Artemether

Artemether

• CAS Number: 71963-77-4
• UNSPSC Description: Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria[1].
• Target Antigen: Parasite
• Type: Natural Products
• Related Pathways: Anti-infection
• Applications: COVID-19-immunoregulation
• Field of Research: Cancer; Infection; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/artemether.html
• Purity: 99.51
• Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL
• Smiles: C[C@H]1[C@@H](OC)O[C@@]2([H])[C@]34[C@@]([C@H](C)CC[C@]41[H])([H])CC[C@@](O2)(C)OO3
• Molecular Weight: 298.37
• References & Citations: [1]Xiao, S., et al., Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop, 2002. 82(2): p. 175-81.|[2]Wu, Z.P., et al., Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. Integr Cancer Ther, 2009. 8(1): p. 88-92.|[3]Wu H, et al. Artemether attenuates LPS-induced inflammatory bone loss by inhibiting osteoclastogenesis and bone resorption via suppression of MAPK signaling pathway. Cell Death Dis. 2018 May 1;9(5):498. |[4]Wang JX, et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br J Pharmacol. 2007 Mar;150(5):652-61.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched